X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Noctiva is indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to void. It is the first FDA-approved therapy for nocturia.
Lead Product(s): Desmopressin Acetate
Therapeutic Area: Urology Product Name: Noctiva
Highest Development Status: ApprovedProduct Type: Peptide
Recipient: Serenity Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition March 09, 2022
Details:
Both Noctiva™ and Natesto® are highly clinically differentiated products with significant patent protection into the 2030s, that Acerus management feels could reach double-digit market share in each of these large market opportunities.
Lead Product(s): Desmopressin Acetate
Therapeutic Area: Urology Product Name: Noctiva
Highest Development Status: ApprovedProduct Type: Peptide
Recipient: Serenity LLC
Deal Size: $16.0 million Upfront Cash: $6.0 million
Deal Type: Agreement February 28, 2022
Details:
Under the terms of the agreement, Verity Pharma will promote NATESTO across the island of Puerto Rico, leveraging its existing commercial footprint and health care network. Acerus will maintain control of distribution, market access, and regulatory activities on the island of Puerto Rico.
Lead Product(s): Testosterone
Therapeutic Area: Endocrinology Product Name: Natesto
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Verity Pharmaceuticals Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 10, 2022
Details:
Under the terms of the agreement, Amneal will sell NATESTO, Testosterone Nasal gel to the company’s existing Endocrinology targets through June 30, 2024.
Lead Product(s): Testosterone
Therapeutic Area: Endocrinology Product Name: Natesto
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Amneal Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 10, 2021
Details:
Acerus will acquire all remaining rights to Natesto in the United States from Aytu. Acerus will assume all product responsibilities associated with Natesto.
Lead Product(s): Testosterone
Therapeutic Area: Endocrinology Product Name: Natesto
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Aytu BioPharma
Deal Size: $7.5 million Upfront Cash: $7.5 million
Deal Type: Divestment April 01, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
